CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 88 enrolled
Drug / intervention
anastrozoledrug
Likely dose
Anastrozole 1 mg orally once dailyAI-extracted
Key inclusion· 3
  • ✓Age 60 years or older
  • ✓Serum testosterone between 150–300 ng/dL
  • ✓Symptoms suggestive of androgen deficiency
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00136695
NCT00136695Phase 2Completed
CompareCT.gov

Anastrozole Administration in Elderly Hypogonadal Men

Massachusetts General Hospital·interventional·Posted Aug 29, 2005·Updated Sep 13, 2022

In Brief

A Phase 2 clinical trial evaluating anastrozole for Hypogonadism. Completed, enrolled 88 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 29, 2005
Enrollment StartOct 1, 2004
Primary CompletionOct 1, 2008
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 20.8 years ago

Interventions

anastrozoledrug

1 mg QD